Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Glioblastoma 2Breast Neoplasms 2Brain Neoplasms 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Gliosarcoma 1Colorectal Neoplasms 1

Interventions

Everolimus 2Cetuximab 2pimonidazole 1pembrolizumab 1advexin 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Paclitaxel 1NVP-BKM120 1Fluorodeoxyglucose F18 1FPP(RGD)2 1Docetaxel 1Cryosurgery 1Cisplatin 1Chemoprevention 1Carboplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Tongue Neoplasms × NVP-BKM120 × Clear all
NCT01816984 2021-10-05

PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

University of Chicago

Phase 1/2 Completed
12 enrolled 11 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡